Clinical Validation of Heart Rate Apps: Mixed-Methods Evaluation Study

BackgroundPhotoplethysmography (PPG) is a proven way to measure heart rate (HR). This technology is already available in smartphones, which allows measuring HR only by using the smartphone. Given the widespread availability of smartphones, this creates a scalable way to enabl...

Full description

Bibliographic Details
Main Authors: Vandenberk, Thijs, Stans, Jelle, Mortelmans, Christophe, Van Haelst, Ruth, Van Schelvergem, Gertjan, Pelckmans, Caroline, Smeets, Christophe JP, Lanssens, Dorien, De Cannière, Hélène, Storms, Valerie, Thijs, Inge M, Vaes, Bert, Vandervoort, Pieter M
Format: Article
Language:English
Published: JMIR Publications 2017-08-01
Series:JMIR mHealth and uHealth
Online Access:http://mhealth.jmir.org/2017/8/e129/
id doaj-afa6b83b595046a6bfd5b2df937b9603
record_format Article
spelling doaj-afa6b83b595046a6bfd5b2df937b96032021-05-03T01:40:55ZengJMIR PublicationsJMIR mHealth and uHealth2291-52222017-08-0158e12910.2196/mhealth.7254Clinical Validation of Heart Rate Apps: Mixed-Methods Evaluation StudyVandenberk, ThijsStans, JelleMortelmans, ChristopheVan Haelst, RuthVan Schelvergem, GertjanPelckmans, CarolineSmeets, Christophe JPLanssens, DorienDe Cannière, HélèneStorms, ValerieThijs, Inge MVaes, BertVandervoort, Pieter M BackgroundPhotoplethysmography (PPG) is a proven way to measure heart rate (HR). This technology is already available in smartphones, which allows measuring HR only by using the smartphone. Given the widespread availability of smartphones, this creates a scalable way to enable mobile HR monitoring. An essential precondition is that these technologies are as reliable and accurate as the current clinical (gold) standards. At this moment, there is no consensus on a gold standard method for the validation of HR apps. This results in different validation processes that do not always reflect the veracious outcome of comparison. ObjectiveThe aim of this paper was to investigate and describe the necessary elements in validating and comparing HR apps versus standard technology. MethodsThe FibriCheck (Qompium) app was used in two separate prospective nonrandomized studies. In the first study, the HR of the FibriCheck app was consecutively compared with 2 different Food and Drug Administration (FDA)-cleared HR devices: the Nonin oximeter and the AliveCor Mobile ECG. In the second study, a next step in validation was performed by comparing the beat-to-beat intervals of the FibriCheck app to a synchronized ECG recording. ResultsIn the first study, the HR (BPM, beats per minute) of 88 random subjects consecutively measured with the 3 devices showed a correlation coefficient of .834 between FibriCheck and Nonin, .88 between FibriCheck and AliveCor, and .897 between Nonin and AliveCor. A single way analysis of variance (ANOVA; P=.61 was executed to test the hypothesis that there were no significant differences between the HRs as measured by the 3 devices. In the second study, 20,298 (ms) R-R intervals (RRI)–peak-to-peak intervals (PPI) from 229 subjects were analyzed. This resulted in a positive correlation (rs=.993, root mean square deviation [RMSE]=23.04 ms, and normalized root mean square error [NRMSE]=0.012) between the PPI from FibriCheck and the RRI from the wearable ECG. There was no significant difference (P=.92) between these intervals. ConclusionsOur findings suggest that the most suitable method for the validation of an HR app is a simultaneous measurement of the HR by the smartphone app and an ECG system, compared on the basis of beat-to-beat analysis. This approach could lead to more correct assessments of the accuracy of HR apps.http://mhealth.jmir.org/2017/8/e129/
collection DOAJ
language English
format Article
sources DOAJ
author Vandenberk, Thijs
Stans, Jelle
Mortelmans, Christophe
Van Haelst, Ruth
Van Schelvergem, Gertjan
Pelckmans, Caroline
Smeets, Christophe JP
Lanssens, Dorien
De Cannière, Hélène
Storms, Valerie
Thijs, Inge M
Vaes, Bert
Vandervoort, Pieter M
spellingShingle Vandenberk, Thijs
Stans, Jelle
Mortelmans, Christophe
Van Haelst, Ruth
Van Schelvergem, Gertjan
Pelckmans, Caroline
Smeets, Christophe JP
Lanssens, Dorien
De Cannière, Hélène
Storms, Valerie
Thijs, Inge M
Vaes, Bert
Vandervoort, Pieter M
Clinical Validation of Heart Rate Apps: Mixed-Methods Evaluation Study
JMIR mHealth and uHealth
author_facet Vandenberk, Thijs
Stans, Jelle
Mortelmans, Christophe
Van Haelst, Ruth
Van Schelvergem, Gertjan
Pelckmans, Caroline
Smeets, Christophe JP
Lanssens, Dorien
De Cannière, Hélène
Storms, Valerie
Thijs, Inge M
Vaes, Bert
Vandervoort, Pieter M
author_sort Vandenberk, Thijs
title Clinical Validation of Heart Rate Apps: Mixed-Methods Evaluation Study
title_short Clinical Validation of Heart Rate Apps: Mixed-Methods Evaluation Study
title_full Clinical Validation of Heart Rate Apps: Mixed-Methods Evaluation Study
title_fullStr Clinical Validation of Heart Rate Apps: Mixed-Methods Evaluation Study
title_full_unstemmed Clinical Validation of Heart Rate Apps: Mixed-Methods Evaluation Study
title_sort clinical validation of heart rate apps: mixed-methods evaluation study
publisher JMIR Publications
series JMIR mHealth and uHealth
issn 2291-5222
publishDate 2017-08-01
description BackgroundPhotoplethysmography (PPG) is a proven way to measure heart rate (HR). This technology is already available in smartphones, which allows measuring HR only by using the smartphone. Given the widespread availability of smartphones, this creates a scalable way to enable mobile HR monitoring. An essential precondition is that these technologies are as reliable and accurate as the current clinical (gold) standards. At this moment, there is no consensus on a gold standard method for the validation of HR apps. This results in different validation processes that do not always reflect the veracious outcome of comparison. ObjectiveThe aim of this paper was to investigate and describe the necessary elements in validating and comparing HR apps versus standard technology. MethodsThe FibriCheck (Qompium) app was used in two separate prospective nonrandomized studies. In the first study, the HR of the FibriCheck app was consecutively compared with 2 different Food and Drug Administration (FDA)-cleared HR devices: the Nonin oximeter and the AliveCor Mobile ECG. In the second study, a next step in validation was performed by comparing the beat-to-beat intervals of the FibriCheck app to a synchronized ECG recording. ResultsIn the first study, the HR (BPM, beats per minute) of 88 random subjects consecutively measured with the 3 devices showed a correlation coefficient of .834 between FibriCheck and Nonin, .88 between FibriCheck and AliveCor, and .897 between Nonin and AliveCor. A single way analysis of variance (ANOVA; P=.61 was executed to test the hypothesis that there were no significant differences between the HRs as measured by the 3 devices. In the second study, 20,298 (ms) R-R intervals (RRI)–peak-to-peak intervals (PPI) from 229 subjects were analyzed. This resulted in a positive correlation (rs=.993, root mean square deviation [RMSE]=23.04 ms, and normalized root mean square error [NRMSE]=0.012) between the PPI from FibriCheck and the RRI from the wearable ECG. There was no significant difference (P=.92) between these intervals. ConclusionsOur findings suggest that the most suitable method for the validation of an HR app is a simultaneous measurement of the HR by the smartphone app and an ECG system, compared on the basis of beat-to-beat analysis. This approach could lead to more correct assessments of the accuracy of HR apps.
url http://mhealth.jmir.org/2017/8/e129/
work_keys_str_mv AT vandenberkthijs clinicalvalidationofheartrateappsmixedmethodsevaluationstudy
AT stansjelle clinicalvalidationofheartrateappsmixedmethodsevaluationstudy
AT mortelmanschristophe clinicalvalidationofheartrateappsmixedmethodsevaluationstudy
AT vanhaelstruth clinicalvalidationofheartrateappsmixedmethodsevaluationstudy
AT vanschelvergemgertjan clinicalvalidationofheartrateappsmixedmethodsevaluationstudy
AT pelckmanscaroline clinicalvalidationofheartrateappsmixedmethodsevaluationstudy
AT smeetschristophejp clinicalvalidationofheartrateappsmixedmethodsevaluationstudy
AT lanssensdorien clinicalvalidationofheartrateappsmixedmethodsevaluationstudy
AT decannierehelene clinicalvalidationofheartrateappsmixedmethodsevaluationstudy
AT stormsvalerie clinicalvalidationofheartrateappsmixedmethodsevaluationstudy
AT thijsingem clinicalvalidationofheartrateappsmixedmethodsevaluationstudy
AT vaesbert clinicalvalidationofheartrateappsmixedmethodsevaluationstudy
AT vandervoortpieterm clinicalvalidationofheartrateappsmixedmethodsevaluationstudy
_version_ 1721485867390861312